The role of TRAIL death receptors in the treatment of hematological malignancies

References

• Ashkenazi A, Dixit V M. Death receptors: signaling and modulation. Science 1998; 281: 1305–1308
   PubMed Web of Science ®Google Scholar
• Kaufmann S H, Steensma D P. On the TRAIL of a new therapy for leukemia. Leukemia 2005; 19: 2195–2202
   PubMed Web of Science ®Google Scholar
• Ashkenazi A, Pai R C, Fong S, Leung S, Lawrence D A, Marsters S A, et al. Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 1999; 104: 155–162
   PubMed Web of Science ®Google Scholar
• Kelley S K, Ashkenazi A. Targeting death receptors in cancer with Apo2L/TRAIL. Curr Opin Pharmacol 2004; 4: 333–339
   PubMed Web of Science ®Google Scholar
• Liabakk N B, Espevik T. Monoclonal antibodies against TRAIL. Vitam Horm 2004; 67: 65–79
   PubMed Web of Science ®Google Scholar
• Ashkenazi A, Dixit V M. Apoptosis control by death and decoy receptors. Curr Opin Cell Biol 1999; 11: 255–260
   PubMed Web of Science ®Google Scholar
• Kabore A F, Johnston J B, Gibson S B. Changes in the apoptotic and survival signaling in cancer cells and their potential therapeutic implications. Curr Cancer Drug Targets 2004; 4: 147–163
   PubMed Web of Science ®Google Scholar
• Schneider P, Thome M, Burns K, Bodmer J L, Hofmann K, Kataoka T, et al. TRAIL receptors 1 (DR4) and 2 (DR5) signal FADD-dependent apoptosis and activate NF-kappaB. Immunity 1997; 7: 831–836
   PubMed Web of Science ®Google Scholar
• Shetty S, Gladden J B, Henson E S, Hu X, Villanueva J, Haney N, et al. Tumor necrosis factor-related apoptosis inducing ligand (TRAIL) up-regulates death receptor 5 (DR5) mediated by NFκB activation in epithelial derived cell lines. Apoptosis 2002; 7: 413–420
   PubMed Web of Science ®Google Scholar
• Aggarwal B B, Bhardwaj U, Takada Y. Regulation of TRAIL-induced apoptosis by ectopic expression of antiapoptotic factors. Vitam Horm 2004; 67: 453–483
   PubMed Web of Science ®Google Scholar
• Di Pietro R, Zauli G. Emerging non-apoptotic functions of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)/Apo2L. J Cell Physiol 2004; 201: 331–340
   PubMed Web of Science ®Google Scholar
• Kim K, Fisher M J, Xu S Q, el-Deiry W S. Molecular determinants of response to TRAIL in killing of normal and cancer cells. Clin Cancer Res 2000; 6: 335–346
   PubMed Web of Science ®Google Scholar
• MacFarlane M, Harper N, Snowden R T, Dyer M J, Barnett G A, Pringle J H, et al. Mechanisms of resistance to TRAIL-induced apoptosis in primary B cell chronic lymphocytic leukaemia. Oncogene 2002; 21: 6809–6818
   PubMed Web of Science ®Google Scholar
• Gomez-Benito M, Martinez-Lorenzo M J, Anel A, Marzo I, Naval J. Membrane expression of DR4, DR5 and caspase-8 levels, but not Mcl-1, determine sensitivity of human myeloma cells to Apo2L/TRAIL. Exp Cell Res 2007; 313: 2378–2388
   PubMed Web of Science ®Google Scholar
• Remacle-Bonnet M, Garrouste F, Baillat G, Andre F, Marvaldi J, Pommier G. Membrane rafts segregate pro- from anti-apoptotic insulin-like growth factor-I receptor signaling in colon carcinoma cells stimulated by members of the tumor necrosis factor superfamily. Am J Pathol 2005; 167: 761–773
   PubMed Web of Science ®Google Scholar
• Vanoosten R L, Moore J M, Ludwig A T, Griffith T S. Depsipeptide (FR901228) enhances the cytotoxic activity of TRAIL by redistributing TRAIL receptor to membrane lipid rafts. Mol Ther 2005; 11: 542–552
   PubMed Web of Science ®Google Scholar
• Delmas D, Rebe C, Micheau O, Athias A, Gambert P, Grazide S, et al. Redistribution of CD95, DR4 and DR5 in rafts accounts for the synergistic toxicity of resveratrol and death receptor ligands in colon carcinoma cells. Oncogene 2004; 23: 8979–8986
   PubMed Web of Science ®Google Scholar
• Secchiero P, Vaccarezza M, Gonelli A, Zauli G. TNF-related apoptosis-inducing ligand (TRAIL): a potential candidate for combined treatment of hematological malignancies. Curr Pharm Des 2004; 10: 3673–3681
   PubMed Web of Science ®Google Scholar
• Merino D, Lalaoui N, Morizot A, Schneider P, Solary E, Micheau O. Differential inhibition of TRAIL-mediated DR5-DISC formation by decoy receptors 1 and 2. Mol Cell Biol 2006; 26: 7046–7055
   PubMed Web of Science ®Google Scholar
• Sheikh M S, Burns T F, Huang Y, Wu G S, Amundson S, Brooks K S, et al. p53-dependent and -independent regulation of the death receptor KILLER/DR5 gene expression in response to genotoxic stress and tumor necrosis factor alpha. Cancer Res 1998; 58: 1593–1598
   PubMed Web of Science ®Google Scholar
• Takimoto R, El-Deiry W S. Wild-type p53 transactivates the KILLER/DR5 gene through an intronic sequence-specific DNA-binding site. Oncogene 2000; 19: 1735–1743
   PubMed Web of Science ®Google Scholar
• Wen J, Ramadevi N, Nguyen D, Perkins C, Worthington E, Bhalla K. Antileukemic drugs increase death receptor 5 levels and enhance apo-2L-induced apoptosis of human acute leukemia cells. Blood 2000; 96: 3900–3906
   PubMed Web of Science ®Google Scholar
• Johnston J B, Kabore A F, Strutinsky J, Hu X, Paul J T, Kropp D M, et al. Role of the TRAIL/APO2-L death receptors in chlorambucil- and fludarabine-induced apoptosis in chronic lymphocytic leukemia. Oncogene 2003; 22: 8356–8369
   PubMed Web of Science ®Google Scholar
• Meng R D, El-Deiry W S. p53-independent upregulation of KILLER/DR5 TRAIL receptor expression by glucocorticoids and interferon-γ. Exp Cell Res 2001; 262: 154–169
   PubMed Web of Science ®Google Scholar
• Gibson S B, Oyer R, Spalding A C, Anderson S M, Johnson G L. Increased expression of death receptors 4 and 5 synergizes the apoptosis response to combined treatment with etoposide and TRAIL. Mol Cell Biol 2000; 20: 205–212
   PubMed Web of Science ®Google Scholar
• Shetty S, Gladden J B, Henson E S, Hu X, Villanueva J, Haney N, et al. Tumor necrosis factor-related apoptosis inducing ligand (TRAIL) up-regulates death receptor 5 (DR5) mediated by NFκB activation in epithelial derived cell lines. Apoptosis 2002; 7: 413–420
   PubMed Web of Science ®Google Scholar
• Yoshida T, Maeda A, Tani N, Sakai T. Promoter structure and transcription initiation sites of the human death receptor 5/TRAIL-R2 gene. FEBS Lett 2001; 507: 381–385
   PubMed Web of Science ®Google Scholar
• Shetty S, Graham B A, Brown J G, Hu X, Vegh-Yarema N, Harding G, et al. Transcription factor NF-κB differentially regulates death receptor 5 expression involving histone deacetylase 1. Mol Cell Biol 2005; 25: 5404–5416
   PubMed Web of Science ®Google Scholar
• Zou W, Liu X, Yue P, Zhou Z, Sporn M B, Lotan R, et al. c-Jun NH2-terminal kinase-mediated up-regulation of death receptor 5 contributes to induction of apoptosis by the novel synthetic triterpenoid methyl-2-cyano-3,12-dioxooleana-1,9-dien-28-oate in human lung cancer cells. Cancer Res 2004; 64: 7570–7578
   PubMed Web of Science ®Google Scholar
• Wang Y, Engels I H, Knee D A, Nasoff M, Deveraux Q L, Quon K C. Synthetic lethal targeting of MYC by activation of the DR5 death receptor pathway. Cancer Cell 2004; 5: 501–512
   PubMed Web of Science ®Google Scholar
• Sun S Y, Liu X, Zou W, Yue P, Marcus A I, Khuri F R. The farnesyltransferase inhibitor Lonafarnib induce CHOP-dependent expression of death receptor 5 leading to induction of apoptosis in human cancer cells. J Biol Chem 2007; 282: 18800–18809
   PubMed Web of Science ®Google Scholar
• Kim Y H, Park J W, Lee J Y, Kwon T K. Sodium butyrate sensitizes TRAIL-mediated apoptosis by induction of transcription from the DR5 gene promoter through Sp1 sites in colon cancer cells. Carcinogenesis 2004; 25: 1813–1820
   PubMed Web of Science ®Google Scholar
• Baritaki S, Huerta-Yepez S, Sakai T, Spandidos D A, Bonavida B. Chemotherapeutic drugs sensitize cancer cells to TRAIL-mediated apoptosis: up-regulation of DR5 and inhibition of Yin Yang 1. Mol Cancer Ther 2007; 6: 1387–1399
   PubMed Web of Science ®Google Scholar
• Guan B, Yue P, Lotan R, Sun S Y. Evidence that the human death receptor 4 is regulated by activator protein 1. Oncogene 2002; 21: 3121–3129
   PubMed Web of Science ®Google Scholar
• Guan B, Yue P, Clayman G L, Sun S Y. Evidence that the death receptor DR4 is a DNA damage-inducible, p53-regulated gene. J Cell Physiol 2001; 188: 98–105
   PubMed Web of Science ®Google Scholar
• Nguyen T, Thomas W, Zhang X D, Gray C, Hersey P. Immunologically-mediated tumour cell apoptosis: the role of TRAIL in T cell and cytokine-mediated responses to melanoma. Forum (Genova) 2000; 10: 243–252
   PubMedGoogle Scholar
• Zauli G, Secchiero P. The role of the TRAIL/TRAIL receptors system in hematopoiesis and endothelial cell biology. Cytokine Growth Factor Rev 2006; 17: 245–257
   PubMed Web of Science ®Google Scholar
• Sedger L M, Glaccum M B, Schuh J C, Kanaly S T, Williamson E, Kayagaki N, et al. Characterization of the in vivo function of TNF-α-related apoptosis-inducing ligand, TRAIL/Apo2L, using TRAIL/Apo2L gene-deficient mice. Eur J Immunol 2002; 32: 2246–2254
   PubMed Web of Science ®Google Scholar
• Rubio-Moscardo F, Blesa D, Mestre C, Siebert R, Balasas T, Benito A, et al. Characterization of 8p21.3 chromosomal deletions in B-cell lymphoma: TRAIL-R1 and TRAIL-R2 as candidate dosage-dependent tumor suppressor genes. Blood 2005; 106: 3214–3222
   PubMed Web of Science ®Google Scholar
• Lee S H, Shin M S, Kim H S, Lee H K, Park W S, Kim S Y, et al. Alterations of the DR5/TRAIL receptor 2 gene in non-small cell lung cancers. Cancer Res 1999; 59: 5683–5686
   PubMed Web of Science ®Google Scholar
• Lee S H, Shin M S, Kim H S, Lee H K, Park W S, Kim S Y, et al. Somatic mutations of TRAIL-receptor 1 and TRAIL-receptor 2 genes in non-Hodgkin's lymphoma. Oncogene 2001; 20: 399–403
   PubMed Web of Science ®Google Scholar
• Liu L G, Tanaka H, Ito K, Ito T, Sultana T A, Kyo T, et al. Absence of gene mutation in TRAIL receptor 1 (TRAIL-R1) and TRAIL receptor 2 (TRAIL-R2) in chronic myelogenous leukemia and myelodysplastic syndrome, and analysis of mRNA Expressions of TRAIL and TRAIL-related genes in chronic myelogenous leukemia. Acta Haematol 2005; 113: 113–123
   PubMed Web of Science ®Google Scholar
• Wolf S, Mertens D, Pscherer A, Schroeter P, Winkler D, Grone H J, et al. Ala228 variant of trail receptor 1 affecting the ligand binding site is associated with chronic lymphocytic leukemia, mantle cell lymphoma, prostate cancer, head and neck squamous cell carcinoma and bladder cancer. Int J Cancer 2006; 118: 1831–1835
   PubMed Web of Science ®Google Scholar
• Zhang L, Fang B. Mechanisms of resistance to TRAIL-induced apoptosis in cancer. Cancer Gene Ther 2005; 12: 228–237
   PubMed Web of Science ®Google Scholar
• Falschlehner C, Emmerich C H, Gerlach B, Walczak H. TRAIL signalling: decisions between life and death. Int J Biochem Cell Biol 2007; 39: 1462–1475
   PubMed Web of Science ®Google Scholar
• Pedersen I M, Kitada S, Leoni L M, Zapata J M, Karras J G, Tsukada N, et al. Protection of CLL B cells by a follicular dendritic cell line is dependent on induction of Mcl-1. Blood 2002; 100: 1795–1801
   PubMed Web of Science ®Google Scholar
• Saxena A, Viswanathan S, Moshynska O, Tandon P, Sankaran K, Sheridan D P. Mcl-1 and Bcl-2/Bax ratio are associated with treatment response but not with Rai stage in B-cell chronic lymphocytic leukemia. Am J Hematol 2004; 75: 22–33
   PubMed Web of Science ®Google Scholar
• Johnston J B, Paul J T, Neufeld N J, Haney N, Kropp D M, Hu X, et al. Role of myeloid cell factor-1 (Mcl-1) in chronic lymphocytic leukemia. Leuk Lymphoma 2004; 45: 2017–2027
   PubMed Web of Science ®Google Scholar
• Gelinas C, White E. BH3-only proteins in control: specificity regulates MCL-1 and BAK-mediated apoptosis. Genes Dev 2005; 19: 1263–1268
   PubMed Web of Science ®Google Scholar
• Yagita H, Takeda K, Hayakawa Y, Smyth M J, Okumura K. TRAIL and its receptors as targets for cancer therapy. Cancer Sci 2004; 95: 777–783
   PubMed Web of Science ®Google Scholar
• Shrader M, Pino M S, Lashinger L, Bar-Eli M, Adam L, Dinney C P, et al. Gefitinib reverses TRAIL resistance in human bladder cancer cell lines via inhibition of AKT-mediated X-linked inhibitor of apoptosis protein expression. Cancer Res 2007; 67: 1430–1435
   PubMed Web of Science ®Google Scholar
• Wang S, El-Deiry W S. TRAIL and apoptosis induction by TNF-family death receptors. Oncogene 2003; 22: 8628–8633
   PubMed Web of Science ®Google Scholar
• Lee T J, Jung E M, Lee J T, Kim S, Park J W, Choi K S, et al. Mithramycin A sensitizes cancer cells to TRAIL-mediated apoptosis by down-regulation of XIAP gene promoter through Sp1 sites. Mol Cancer Ther 2006; 5: 2737–2746
   PubMed Web of Science ®Google Scholar
• Kim D M, Koo S Y, Jeon K, Kim M H, Lee J, Hong C Y, et al. Rapid induction of apoptosis by combination of flavopiridol and tumor necrosis factor (TNF)-α or TNF-related apoptosis-inducing ligand in human cancer cell lines. Cancer Res 2003; 63: 621–626
   PubMed Web of Science ®Google Scholar
• Akay C, Gazitt Y. Arsenic trioxide selectively induces early and extensive apoptosis via the APO2/caspase-8 pathway engaging the mitochondrial pathway in myeloma cells with mutant p53. Cell Cycle 2003; 2: 358–368
   PubMed Web of Science ®Google Scholar
• Liu Q, Hilsenbeck S, Gazitt Y. Arsenic trioxide-induced apoptosis in myeloma cells: p53-dependent G1 or G2/M cell cycle arrest, activation of caspase-8 or caspase-9, and synergy with APO2/TRAIL. Blood 2003; 101: 4078–4087
   PubMed Web of Science ®Google Scholar
• Nimmanapalli R, Porosnicu M, Nguyen D, Worthington E, O'Bryan E, Perkins C, et al. Cotreatment with STI-571 enhances tumor necrosis factor α-related apoptosis-inducing ligand (TRAIL or apo-2L)-induced apoptosis of Bcr-Abl-positive human acute leukemia cells. Clin Cancer Res 2001; 7: 350–357
   PubMed Web of Science ®Google Scholar
• Kabore A F, Sun J, Hu X, McCrea K, Johnston J B, Gibson S. The TRAIL apoptotic pathway mediates proteasome inhibitor induced apoptosis in primary chronic lymphocytic leukemia cells. Apoptosis 2006; 11: 1175–1193
   PubMed Web of Science ®Google Scholar
• MacFarlane M, Inoue S, Kohlhaas S L, Majid A, Harper N, Kennedy D B, et al. Chronic lymphocytic leukemic cells exhibit apoptotic signaling via TRAIL-R1. Cell Death Differ 2005; 12: 773–782
   PubMed Web of Science ®Google Scholar
• Insinga A, Monestiroli S, Ronzoni S, Gelmetti V, Marchesi F, Viale A, et al. Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway. Nat Med 2005; 11: 71–76
   PubMed Web of Science ®Google Scholar
• Pan Q, Liu B, Liu J, Cai R, Wang Y, Qian C. Synergistic induction of tumor cell death by combining cisplatin with an oncolytic adenovirus carrying TRAIL. Mol Cell Biochem 2007; 304: 315–323
   PubMed Web of Science ®Google Scholar
• Duiker E W, Mom C H, de Jong S, Willemse P H, Gietema J A, van der Zee A G, et al. The clinical trail of TRAIL. Eur J Cancer 2006; 42: 2233–2240
   PubMed Web of Science ®Google Scholar
• Yee L, Fanale M, Dimick K, Calvert S, Robbins C, Ing J, et al. A phase 1B safety and pharmacokinetic (PK) study of recombinant human Apo2L/TRAIL in combination with rituximab in patients with low grade non-Hodgkin lymphoma. American Society of Clinical Oncology (ASCO) 2007; Abstract 8078
   Google Scholar
• Georgakis G V, Li Y, Humphreys R, Andreeff M, O'Brien S, Younes M, et al. Activity of selective fully human agonistic antibodies to the TRAIL death receptors TRAIL-R1 and TRAIL-R2 in primary and cultured lymphoma cells: induction of apoptosis and enhancement of doxorubicin- and bortezomib-induced cell death. Br J Haematol 2005; 130: 501–510
   PubMed Web of Science ®Google Scholar
• Sikic B I, Wakelee H A, Mehren M V, Lewis N, Calvert A H, Plummer E R, et al. A phase 1b study to access the safety of lexatumumab, a human monoclonal antibody that activates TRAIL-R2 in combination with gemitabine, pemetrexed, doxorubicin, or FOLFIRI. American Society of Clinical Oncology (ASCO) 2007; Abstract 14006
   Google Scholar
• Fanale M A, Younes A. Monoclonal antibodies in the treatment of non-Hodgkin's lymphoma. Drugs 2007; 67: 333–350
   PubMed Web of Science ®Google Scholar